Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2006-12

AUTHORS

David Cella, Lesley Fallowfield, Peter Barker, Jack Cuzick, Gershon Locker, Anthony Howell, On behalf of the ATAC Trialistsȁ9 Group

ABSTRACT

The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer. Here we report mature HRQoL outcomes from the ATAC trial, comparing anastrozole with tamoxifen as primary adjuvant therapy for postmenopausal women with localized breast cancer. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire plus endocrine subscale (ES) at baseline, 3 and 6 months, and every 6 months thereafter. Baseline characteristics in the HRQoL sub-protocol were well balanced between the anastrozole (n = 335) and tamoxifen (n = 347) groups in the primary analysis population. As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years. There were no statistically significant differences between treatment groups in ES total scores. Consistent with the 2-year analysis, there were differences between treatment groups in patient-reported side effects: diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen. Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen. In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups. More... »

PAGES

273-284

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-006-9260-6

DOI

http://dx.doi.org/10.1007/s10549-006-9260-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1007691459

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/16944295


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anastrozole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Status", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitriles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Odds Ratio", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Dropouts", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postmenopause", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "Feinberg School of Medicine, Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Suite 100, 60201, Evanston, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cella", 
        "givenName": "David", 
        "id": "sg:person.012000260477.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012000260477.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Brighton and Sussex Medical School", 
          "id": "https://www.grid.ac/institutes/grid.414601.6", 
          "name": [
            "Psychosocial Oncology Group, Brighton & Sussex Medical School, Cancer Research UK, Brighton, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fallowfield", 
        "givenName": "Lesley", 
        "id": "sg:person.01063165262.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063165262.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United Kingdom)", 
          "id": "https://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca, Alderley Park, Macclesfield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barker", 
        "givenName": "Peter", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cancer Research UK", 
          "id": "https://www.grid.ac/institutes/grid.11485.39", 
          "name": [
            "Wolfson Institute of Preventive Medicine, Cancer Research UK, London, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cuzick", 
        "givenName": "Jack", 
        "id": "sg:person.01136740201.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136740201.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Feinberg School of Medicine, Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Suite 100, 60201, Evanston, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Locker", 
        "givenName": "Gershon", 
        "id": "sg:person.01272673224.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272673224.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Manchester", 
          "id": "https://www.grid.ac/institutes/grid.5379.8", 
          "name": [
            "Department of Medical Oncology, Christie Hospital, Cancer Research UK, University of Manchester, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Howell", 
        "givenName": "Anthony", 
        "id": "sg:person.01005610111.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005610111.35"
        ], 
        "type": "Person"
      }, 
      {
        "familyName": "On behalf of the ATAC Trialists\u02019 Group", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2005.03.3654", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000710653"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(05)66544-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001690029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(05)66544-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001690029"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdj044", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005294863"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa040331", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007910288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.09.121", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014233996"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0163278705275340", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014870899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/0163278705275340", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014870899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.11.181", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018532459"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.11.181", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018532459"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(04)17666-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031625479"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1006263818115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032185952", 
          "https://doi.org/10.1023/a:1006263818115"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-55647-0_9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034162993", 
          "https://doi.org/10.1007/978-3-642-55647-0_9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-642-55647-0_9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034162993", 
          "https://doi.org/10.1007/978-3-642-55647-0_9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(02)09088-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039621510"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.08.029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041745060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jclinepi.2004.01.012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049369635"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.2.322", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074768316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1993.11.3.570", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1082809601"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1997.15.3.974", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083057211"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2006-12", 
    "datePublishedReg": "2006-12-01", 
    "description": "The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer. Here we report mature HRQoL outcomes from the ATAC trial, comparing anastrozole with tamoxifen as primary adjuvant therapy for postmenopausal women with localized breast cancer. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire plus endocrine subscale (ES) at baseline, 3 and 6 months, and every 6 months thereafter. Baseline characteristics in the HRQoL sub-protocol were well balanced between the anastrozole (n = 335) and tamoxifen (n = 347) groups in the primary analysis population. As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years. There were no statistically significant differences between treatment groups in ES total scores. Consistent with the 2-year analysis, there were differences between treatment groups in patient-reported side effects: diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen. Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen. In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10549-006-9260-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "100"
      }
    ], 
    "name": "Quality of Life of Postmenopausal Women in the ATAC (\u201cArimidex\u201d, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer", 
    "pagination": "273-284", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "24a2e793006455c2e95d9174a9ffe550bfdffa496963c99468f00070ccc232f0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "16944295"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-006-9260-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1007691459"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-006-9260-6", 
      "https://app.dimensions.ai/details/publication/pub.1007691459"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T14:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000373_0000000373/records_13093_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10549-006-9260-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9260-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9260-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9260-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-006-9260-6'


 

This table displays all metadata directly associated to this object as RDF triples.

250 TRIPLES      21 PREDICATES      65 URIs      41 LITERALS      29 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-006-9260-6 schema:about N0abf433befda4f0ab2ae584fc8f0705c
2 N10b6973780524e34802063fd88bddaa0
3 N1389a6224e624d519079ccf8245351f1
4 N254f543d3ba647cb8e3ce32cb704aba5
5 N2bb0f450a11a4a7d8435354f8a87f004
6 N333a2bcec4164c4e91eae10b13df9dc1
7 N389fb4f50f4241fe98b9d7990b8d84b8
8 N3907a050a6704c1aa86451a8a37953d1
9 N5374a9145c8c479c91aa4293dd278864
10 N5ce3094b50724403b796bd75a0d4b62c
11 N68e567216df0468d9d3cb5ca9c90526f
12 N6a4da7923ce0481390ffa8944d34760b
13 N868b03af3f1d4cfc9bde987d796e7cc7
14 N8b96b66afdee4792b0e80d2c9b6f9360
15 N97dc91c4946544c4824ca629d9e32db9
16 N9b974f5e3d08417d8079ffbbe3dabb8f
17 Na689916cdba347b9a93c289dcb201b3f
18 Nbe2e10106dc649af92aa0dce4de62dee
19 Nd82744d537dd4b63b11c8c95df688a4f
20 Ne2627881bcb646fa81e5c00a4d1c8562
21 anzsrc-for:11
22 anzsrc-for:1112
23 schema:author N9ce8588f238e432a9e60c558c1cc3724
24 schema:citation sg:pub.10.1007/978-3-642-55647-0_9
25 sg:pub.10.1023/a:1006263818115
26 https://doi.org/10.1016/j.jclinepi.2004.01.012
27 https://doi.org/10.1016/s0140-6736(02)09088-8
28 https://doi.org/10.1016/s0140-6736(04)17666-6
29 https://doi.org/10.1016/s0140-6736(05)66544-0
30 https://doi.org/10.1056/nejmoa040331
31 https://doi.org/10.1093/annonc/mdj044
32 https://doi.org/10.1177/0163278705275340
33 https://doi.org/10.1200/jco.1993.11.3.570
34 https://doi.org/10.1200/jco.1997.15.3.974
35 https://doi.org/10.1200/jco.2001.19.2.322
36 https://doi.org/10.1200/jco.2004.08.029
37 https://doi.org/10.1200/jco.2005.03.3654
38 https://doi.org/10.1200/jco.2005.09.121
39 https://doi.org/10.1200/jco.2005.11.181
40 schema:datePublished 2006-12
41 schema:datePublishedReg 2006-12-01
42 schema:description The impact of treatment on health-related quality of life (HRQoL) is an important consideration in the adjuvant treatment of operable breast cancer. Here we report mature HRQoL outcomes from the ATAC trial, comparing anastrozole with tamoxifen as primary adjuvant therapy for postmenopausal women with localized breast cancer. Patients completed the Functional Assessment of Cancer Therapy-Breast (FACT-B) questionnaire plus endocrine subscale (ES) at baseline, 3 and 6 months, and every 6 months thereafter. Baseline characteristics in the HRQoL sub-protocol were well balanced between the anastrozole (n = 335) and tamoxifen (n = 347) groups in the primary analysis population. As with previously published results at 2 years, there was no statistically significant difference in the Trial Outcome Index of the FACT-B, the primary endpoint of the study, between treatments at 5 years. There were no statistically significant differences between treatment groups in ES total scores. Consistent with the 2-year analysis, there were differences between treatment groups in patient-reported side effects: diarrhea (anastrozole 3.1% vs. tamoxifen 1.3%), vaginal dryness (18.5% vs. 9.1%), diminished libido (34.0% vs. 26.1%), and dyspareunia (17.3% vs. 8.1%) were significantly more frequent with anastrozole compared to tamoxifen. Dizziness (3.1% vs. 5.4%) and vaginal discharge (1.2% vs. 5.2%) were significantly less frequent with anastrozole compared to tamoxifen. In this, the first report of HRQoL over 5 years of initial adjuvant therapy with an aromatase inhibitor, we conclude that anastrozole and tamoxifen had similar impacts on HRQoL, which was maintained or slightly improved during the treatment period for both groups.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree false
46 schema:isPartOf Nc0380e84484b4be391f6b6bb4ea9d9b4
47 Nfb933a6644464be1b31f0e50486859c8
48 sg:journal.1092777
49 schema:name Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer
50 schema:pagination 273-284
51 schema:productId N009e2411c91d4ad58067b5fff82ca619
52 N4fed55da48af498b9e2fa38ee219380b
53 N74f9b80df75a43b4a79f9ce120a034c9
54 Nd6c226b0d9e74f51a59b2d7645313718
55 Nf613206c7ef5442388e1357ec787d713
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007691459
57 https://doi.org/10.1007/s10549-006-9260-6
58 schema:sdDatePublished 2019-04-11T14:30
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher N0f21b42913284fcebd5af6560ef5f3a2
61 schema:url http://link.springer.com/10.1007%2Fs10549-006-9260-6
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N009e2411c91d4ad58067b5fff82ca619 schema:name dimensions_id
66 schema:value pub.1007691459
67 rdf:type schema:PropertyValue
68 N0abf433befda4f0ab2ae584fc8f0705c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Patient Dropouts
70 rdf:type schema:DefinedTerm
71 N0f21b42913284fcebd5af6560ef5f3a2 schema:name Springer Nature - SN SciGraph project
72 rdf:type schema:Organization
73 N10b6973780524e34802063fd88bddaa0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Time Factors
75 rdf:type schema:DefinedTerm
76 N1389a6224e624d519079ccf8245351f1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Postmenopause
78 rdf:type schema:DefinedTerm
79 N254f543d3ba647cb8e3ce32cb704aba5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Surveys and Questionnaires
81 rdf:type schema:DefinedTerm
82 N2bb0f450a11a4a7d8435354f8a87f004 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Health Status
84 rdf:type schema:DefinedTerm
85 N333a2bcec4164c4e91eae10b13df9dc1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Triazoles
87 rdf:type schema:DefinedTerm
88 N389fb4f50f4241fe98b9d7990b8d84b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Female
90 rdf:type schema:DefinedTerm
91 N3907a050a6704c1aa86451a8a37953d1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Chemotherapy, Adjuvant
93 rdf:type schema:DefinedTerm
94 N3ed0b99908b44ad38eb3b86673787a9d rdf:first N5a9c23e7e2c34c068e3896b2ce0874fe
95 rdf:rest Nc6a6fe6500db4ec1a413c52563c68c17
96 N4fed55da48af498b9e2fa38ee219380b schema:name nlm_unique_id
97 schema:value 8111104
98 rdf:type schema:PropertyValue
99 N5374a9145c8c479c91aa4293dd278864 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Tamoxifen
101 rdf:type schema:DefinedTerm
102 N5a9c23e7e2c34c068e3896b2ce0874fe schema:affiliation https://www.grid.ac/institutes/grid.417815.e
103 schema:familyName Barker
104 schema:givenName Peter
105 rdf:type schema:Person
106 N5ce3094b50724403b796bd75a0d4b62c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Risk Assessment
108 rdf:type schema:DefinedTerm
109 N60f94da6f0784341a4e050170615a8ae schema:name Feinberg School of Medicine, Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Suite 100, 60201, Evanston, IL, USA
110 rdf:type schema:Organization
111 N666bb212c2a84ff0be418ec52ddc16fa rdf:first sg:person.01005610111.35
112 rdf:rest Nbf35df17ec1b4450ab227cfc4b710101
113 N68e567216df0468d9d3cb5ca9c90526f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Humans
115 rdf:type schema:DefinedTerm
116 N6a4da7923ce0481390ffa8944d34760b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Quality of Life
118 rdf:type schema:DefinedTerm
119 N6fb0759c1a244eccbf20ba78448beae4 rdf:first sg:person.01063165262.37
120 rdf:rest N3ed0b99908b44ad38eb3b86673787a9d
121 N74f9b80df75a43b4a79f9ce120a034c9 schema:name pubmed_id
122 schema:value 16944295
123 rdf:type schema:PropertyValue
124 N868b03af3f1d4cfc9bde987d796e7cc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Nitriles
126 rdf:type schema:DefinedTerm
127 N8b96b66afdee4792b0e80d2c9b6f9360 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Odds Ratio
129 rdf:type schema:DefinedTerm
130 N97dc91c4946544c4824ca629d9e32db9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Antineoplastic Combined Chemotherapy Protocols
132 rdf:type schema:DefinedTerm
133 N9b974f5e3d08417d8079ffbbe3dabb8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Anastrozole
135 rdf:type schema:DefinedTerm
136 N9ce8588f238e432a9e60c558c1cc3724 rdf:first sg:person.012000260477.10
137 rdf:rest N6fb0759c1a244eccbf20ba78448beae4
138 Na689916cdba347b9a93c289dcb201b3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Double-Blind Method
140 rdf:type schema:DefinedTerm
141 Nbe2e10106dc649af92aa0dce4de62dee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Breast Neoplasms
143 rdf:type schema:DefinedTerm
144 Nbf35df17ec1b4450ab227cfc4b710101 rdf:first Nd24a58192ba1457f9e3386d88e73e0cf
145 rdf:rest rdf:nil
146 Nc0380e84484b4be391f6b6bb4ea9d9b4 schema:volumeNumber 100
147 rdf:type schema:PublicationVolume
148 Nc6a6fe6500db4ec1a413c52563c68c17 rdf:first sg:person.01136740201.43
149 rdf:rest Ndeae9dc243424392b64502863a5de846
150 Nd24a58192ba1457f9e3386d88e73e0cf schema:familyName On behalf of the ATAC Trialistsȁ9 Group
151 rdf:type schema:Person
152 Nd6c226b0d9e74f51a59b2d7645313718 schema:name doi
153 schema:value 10.1007/s10549-006-9260-6
154 rdf:type schema:PropertyValue
155 Nd82744d537dd4b63b11c8c95df688a4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Treatment Outcome
157 rdf:type schema:DefinedTerm
158 Ndeae9dc243424392b64502863a5de846 rdf:first sg:person.01272673224.16
159 rdf:rest N666bb212c2a84ff0be418ec52ddc16fa
160 Ne2627881bcb646fa81e5c00a4d1c8562 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Follow-Up Studies
162 rdf:type schema:DefinedTerm
163 Nf613206c7ef5442388e1357ec787d713 schema:name readcube_id
164 schema:value 24a2e793006455c2e95d9174a9ffe550bfdffa496963c99468f00070ccc232f0
165 rdf:type schema:PropertyValue
166 Nfb933a6644464be1b31f0e50486859c8 schema:issueNumber 3
167 rdf:type schema:PublicationIssue
168 Nffb1701776314cef9f8e2c2539613822 schema:name Feinberg School of Medicine, Evanston Northwestern Healthcare and Northwestern University, 1001 University Place, Suite 100, 60201, Evanston, IL, USA
169 rdf:type schema:Organization
170 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
171 schema:name Medical and Health Sciences
172 rdf:type schema:DefinedTerm
173 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
174 schema:name Oncology and Carcinogenesis
175 rdf:type schema:DefinedTerm
176 sg:journal.1092777 schema:issn 0167-6806
177 1573-7217
178 schema:name Breast Cancer Research and Treatment
179 rdf:type schema:Periodical
180 sg:person.01005610111.35 schema:affiliation https://www.grid.ac/institutes/grid.5379.8
181 schema:familyName Howell
182 schema:givenName Anthony
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005610111.35
184 rdf:type schema:Person
185 sg:person.01063165262.37 schema:affiliation https://www.grid.ac/institutes/grid.414601.6
186 schema:familyName Fallowfield
187 schema:givenName Lesley
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063165262.37
189 rdf:type schema:Person
190 sg:person.01136740201.43 schema:affiliation https://www.grid.ac/institutes/grid.11485.39
191 schema:familyName Cuzick
192 schema:givenName Jack
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01136740201.43
194 rdf:type schema:Person
195 sg:person.012000260477.10 schema:affiliation Nffb1701776314cef9f8e2c2539613822
196 schema:familyName Cella
197 schema:givenName David
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012000260477.10
199 rdf:type schema:Person
200 sg:person.01272673224.16 schema:affiliation N60f94da6f0784341a4e050170615a8ae
201 schema:familyName Locker
202 schema:givenName Gershon
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01272673224.16
204 rdf:type schema:Person
205 sg:pub.10.1007/978-3-642-55647-0_9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034162993
206 https://doi.org/10.1007/978-3-642-55647-0_9
207 rdf:type schema:CreativeWork
208 sg:pub.10.1023/a:1006263818115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032185952
209 https://doi.org/10.1023/a:1006263818115
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1016/j.jclinepi.2004.01.012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049369635
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1016/s0140-6736(02)09088-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039621510
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1016/s0140-6736(04)17666-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031625479
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1016/s0140-6736(05)66544-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001690029
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1056/nejmoa040331 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007910288
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1093/annonc/mdj044 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005294863
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1177/0163278705275340 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014870899
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.1993.11.3.570 schema:sameAs https://app.dimensions.ai/details/publication/pub.1082809601
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1200/jco.1997.15.3.974 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083057211
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1200/jco.2001.19.2.322 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074768316
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1200/jco.2004.08.029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041745060
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1200/jco.2005.03.3654 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000710653
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1200/jco.2005.09.121 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014233996
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1200/jco.2005.11.181 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018532459
238 rdf:type schema:CreativeWork
239 https://www.grid.ac/institutes/grid.11485.39 schema:alternateName Cancer Research UK
240 schema:name Wolfson Institute of Preventive Medicine, Cancer Research UK, London, UK
241 rdf:type schema:Organization
242 https://www.grid.ac/institutes/grid.414601.6 schema:alternateName Brighton and Sussex Medical School
243 schema:name Psychosocial Oncology Group, Brighton & Sussex Medical School, Cancer Research UK, Brighton, UK
244 rdf:type schema:Organization
245 https://www.grid.ac/institutes/grid.417815.e schema:alternateName AstraZeneca (United Kingdom)
246 schema:name AstraZeneca, Alderley Park, Macclesfield, UK
247 rdf:type schema:Organization
248 https://www.grid.ac/institutes/grid.5379.8 schema:alternateName University of Manchester
249 schema:name Department of Medical Oncology, Christie Hospital, Cancer Research UK, University of Manchester, Manchester, UK
250 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...